Stanford psychiatrist makes Grassley’s list Continuing his I-Spy search for undisclosed financial ties among academic physicians, Sen. Chuck Grassley (R-IA) added Dr. Alan Schatzberg, head of psychiatry at Stanford School of Medicine to the Congressional

For us, the most shocking thing in Melody Petersen’s book Our Daily Meds was her description of a special voicemail system Parke-Davis (a division of Warner Lambert) set up for Neurontin, the epilepsy drug the company illegally marketed for just about any

Back in February, we ran a guest blog post here on the Prescription Access Litigation blog titled "Nat’l Women’s Health Network debunks 'Hands Off My Estrogens!' Ad on FDA enforcement re: “bioidential hormones”" The post addressed ads that a group called

A bill that would allow pharmacies to distribute customers’ information and provide reminder mail about their prescriptions has made it through the California Senate and is waiting for review by the Assembly.  Senate bill 1096, the Confidential of Medical

Making the rounds The Reader starts with the most continental news in the world of pharmaceutical conflict of interest this week: the AMSA PharmFree Scorecard, released with RxP last week, made sea-to-sea headlines and/or waves. Here’s a handful of storie

Grades are up at the AMSA PharmFree Scorecard, which assessed the conflict of interest policies of all 150 medical schools in the U.S.   To develop the scorecard, the American Medical Student Association teamed up with RxP, which has been working to help

Dean Baker, from the Center for Economic and Policy Research, has a great piece up on truthout.org called Firefighters and Prescription Drugs. Baker has frequently written in the past on the perversity of our current patent-based system for developing

Regular readers of the Prescription Access Litigation Blog will have noticed that things have been quiet around here lately, despite no shortage of interesting news. As a small nonprofit, sometimes we get too busy to blog. So what better to satisfy your

A couple of weeks ago, GlaxoSmithKline Chief Chris Viehbacher tried out the bully pulpit on Massachusetts lawmakers considering a gift ban for physicians.  Too early to tell, but it may have done more harm than good.  So now pharma companies are trying a